Alzheimer's Disease
Conditions
Interventions
Group A (Memory Encoding Phase):The subjects underwent two memory tests on the first and third days of the intervention, with stimulation provided during the picture learning phase, one being a sham s
Group B (Memory Consolidation Period):Subjects were given real/false stimuli during the sleep stages on the first and third days. The order of real/false stimuli was also randomized.
Group C (Memory Retrieval Phase):The subjects were given stimuli during the test phases on the first and third days, with one being a sham stimulus and the other a real stimulus. There was a one-day i
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 50 years, any gender; 2. Meets the clinical diagnostic criteria for AD: (1) Insidious onset; (2) Reported or observed clear history of cognitive deterioration; (3) History and examinations confirm that early and significant cognitive impairment has one of the following: memory symptoms and non-memory symptoms; (4) Meets exclusion criteria. 3. Patients with Aß (+) AD dementia who meet the NIA-AA (2024) diagnostic criteria; 4. Clinical dementia assessment scales: CDR >= 1, MMSE <= 26 (adjusted according to educational level: illiterate <= 22, primary school <= 23, middle school <= 24, university <= 26), MoCA <= 18. 5. Voluntarily signs the informed consent form, is able and willing to comply with all requirements, including treatment, follow-up, and other study procedures as planned.
Exclusion criteria
Exclusion criteria: 1. Mental illnesses, such as depression, anxiety, schizophrenia, sleep disorders, and other neurological diseases, including cerebral infarction, Parkinson's disease, epilepsy, and brain tumors; 2. Pathological factors that may lead to cognitive decline, such as severe anemia, severe liver and kidney dysfunction, hypothyroidism, poisoning, alcohol dependence, etc.; 3. Severe cardiovascular and cerebrovascular diseases, blood disorders, or other serious complications; 4. Abnormal brain MRI, white matter lesions, space-occupying lesions, or other abnormal signals with a Fazekas score >=2; 5. Rapid cognitive decline within a few months, suggesting central nervous system infection, inflammation, or metabolic disorders; 6. Participants who have taken antidepressants, hypnotics, antiepileptic drugs, or similar medications within the past 4 weeks are also excluded; 7. Other conditions judged by the investigator as unsuitable for participating in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The accuracy of image recognition; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety indicators (incidence of adverse events, observation covering the intervention period and follow-up period, recording event types 1-4, frequency, severity, and outcome, researchers determine relevance based on clinical judgment);Neuroelectrophysiological indicators; | — |
Countries
China
Contacts
Public ContactYanjiang Wang
Army Medical Center of PLA
Outcome results
None listed